Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study

Chia Yu Chu, Anwar Al Hammadi, Nancy Agmon-Levin, Nilgun Atakan, Assem Farag, Rand K. Arnaout, Suretha Kannenberg, Kanokvalai Kulthanan, Asmara Mubarak, Fares Zaitoun, Susanne Crowe, Sigrid Malfait, Kathryn Cooke, Elise L. Dekker*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Chronic urticaria (CU) is a condition characterized by recurrent itchy hives and/or angioedema for ≥6 weeks. Most of the data about CU come from western countries with very little information available about CU in Asia, Africa, and the Middle East. Methods: AWARE-AMAC is a 24-month prospective, observational, real-world, non-interventional study in patients aged ≥18 years from Asia, the Middle East, and Africa (AMAC) with CU refractory to H1-antihistamines (H1-AH). The main objective was to describe the real-world experience with CU, including clinical characteristics, presence of angioedema, treatment patterns (shifts between treatment classes and changes within a treatment class), investigator-assessed disease control, and the impact on quality of life. Subgroups of interest were type of CU at Baseline and treatment class (based on 2013 urticaria guidelines). There were no mandatory visits and diagnostic/monitoring procedures additional to routine practice, except the patient diary (7-day Urticaria Activity Score) and patient reported outcome assessments. Results: The focus of the current manuscript is on patients with chronic spontaneous urticaria (CSU), who formed 98% of the sample. Patients were predominantly female (69.6% female, mean age ± SD 39.8 ± 13.29 years). Time since current diagnosis (Mean ± SD) was 28.6 ± 49.06 months. Amongst patients with CSU, 31.0% had comorbid chronic inducible urticaria (CINDU) and 46.4% had a history of angioedema. 91.9% received H1-AH therapy (±other treatments). The most frequently prescribed treatment classes at Baseline were any/combination of medications, not classified under the other 7 treatment classes, named “Others” (30.5%) followed by, omalizumab (OMA; 23.6%) and second-generation H1-AH monotherapy (sgAH; 15.1%). At Month 12, the most prescribed treatment classes (>15%) for patients were OMA (23.5%) and “Other” (21.3%); 19.7% received "No drug". At Month 24, OMA (22.5%), and “Other” (17.9%) were most frequently prescribed; 28.6% received "No drug". Overall, 79.5% of patients had some type of change in treatment. Over the study period, improvement in self-reported QoL increased, which was mirrored by better disease control. Conclusion: In AMAC countries, the non-recommended “Other” treatment class played a major role in the initial management of CU patients. High usage of H1-AH (±other treatments) and OMA was observed. Treatment changes were observed in a majority of patients. Treatment escalation from sgAH was mostly via OMA. Improvement of disease control and QoL was achieved during the study period. Trial registration: Observational study (NA).

Original languageEnglish
Article number100117
JournalWorld Allergy Organization Journal
Volume13
Issue number4
DOIs
StatePublished - Apr 2020
Externally publishedYes

Funding

FundersFunder number
Novartis
Novartis Pharma

    Keywords

    • Chronic spontaneous urticaria
    • Efficacy
    • Omalizumab
    • Quality of life
    • Second-generation antihistamines

    Fingerprint

    Dive into the research topics of 'Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study'. Together they form a unique fingerprint.

    Cite this